**Table S1. Grading of Adverse Health Outcomes** 

|  | Grading of Adverse Health Outcomes a  |  |   |  |                                      |
|--|---|--|---|--|--------------------------------------|
| Patient-reported AHO                             | Platinum Study item(s) used to assign severity grade  | Grade 1  | Grade 2   | Grade 3  | Grade 4                              |
| Hearing<br>loss/impairment <sup>b</sup>          | Difficulty hearing <sup>c</sup> Reduced hearing <sup>d</sup> Hearing loss requiring a hearing aid <sup>e</sup> Complete deafness <sup>e</sup>   | A little<br>(difficulty<br>hearing or<br>reduced<br>hearing) | Quite a bit or<br>very much<br>(difficulty<br>hearing or<br>reduced<br>hearing) | Hearing loss requiring a hearing aid in one or both ears or complete deafness in one ear | Complete<br>deafness in<br>both ears |
| Tinnitus   | Ringing in ears <sup>d</sup>  | A little   | Quite a bit   | Very much  | NA <sup>f</sup>                      |
| Peripheral<br>Sensory<br>Neuropathy <sup>b</sup> | Tingling fingers/hands or toes/feet ° Numbness in fingers/hands or toes/feet ° Shooting or burning pain in fingers/hands or toes/feet ° Difficulty distinguishing between hot and cold water ° Problems standing/walking because of difficulty feeling ground under feet ° Pain and tingling in fingers/hands or toes/feet description medication use 9 | A little   | Quite a bit   | Very much  | NA <sup>f</sup>                      |
| Kidney Disease                                   | Told by doctor of kidney disease Prescription medication use <sup>9</sup>   | Have kidney<br>disease                                       | Have kidney disease AND medication use  | NA <sup>f</sup>  | NA <sup>f</sup>                      |

Abbreviations: AHO, adverse health outcome; NA, not captured; TC, testicular cancer

<sup>&</sup>lt;sup>a</sup> The table is adapted and modified from Kerns et al.(15,30).

<sup>&</sup>lt;sup>b</sup> For conditions based on more than one question, the severity grade was assigned based on the response reporting the greatest or most severe symptom.

<sup>°</sup> Item was assessed with the European Organization for Research and Treatment of Cancer Chemotherapy Induced Peripheral Neuropathy 20-item quality-of-life questionnaire (EORTC-CIPN-20) on the basis of symptoms experienced over the past 4 weeks. Participants were asked to report if they had not at all, a little, quite a bit, or very much of the AHO (26).

<sup>&</sup>lt;sup>d</sup> Item was assessed with the Scale for Chemotherapy-Induced Long-Term Neurotoxicity (SCIN) questionnaire on the basis of symptoms experienced over the past 4 weeks. Participants were asked to report if they had not at all, a little, quite a bit, or very much of the AHO (25).

e Item is from the Hearing Handicap Inventory by Ventry and Weinstein and assessed symptoms at the time of clinical evaluation (27). For each item, participants were asked to report the age (in years) at first occurrence. If onset of symptoms was prior to age of TC diagnosis, those responses were not considered when assigning severity grade.

f Data needed to assign grade were not captured.

<sup>&</sup>lt;sup>9</sup> Assessed through patient-reported prescription medications taken for at least the past 4 weeks. For each prescription medication, participants were asked to report the indication of use and if they started the medication before/during/after chemotherapy. Prescription medications were only used to assign grade if the participant reported that the indication was for the given AHO and the medication was started during or after chemotherapy.